New study tracks Pluvicto's Real-World safety for advanced prostate cancer
NCT ID NCT06514521
First seen Jan 05, 2026 · Last updated May 07, 2026 · Updated 22 times
Summary
This study is tracking the safety and effectiveness of the drug Pluvicto in men with advanced prostate cancer that has spread and no longer responds to hormone therapy. About 278 participants in South Korea will be observed during their normal treatment. The main goal is to record any side effects and see how well the drug works in everyday medical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGSeongnam-si, Gyeonggi-do, 13620, South Korea
-
Novartis Investigative Site
RECRUITINGGyeonggi-do, Korea, 10408, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, Seoul, 06351, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 03722, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 05505, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 06591, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 110-744, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 139-706, South Korea
Conditions
Explore the condition pages connected to this study.